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A 3-Year Randomized Clinical Trial of MiSight Lenses for
Myopia Control
Paul Chamberlain, BSc,1* Sofia C. Peixoto-de-Matos, MSc,2 Nicola S. Logan, PhD,3 Cheryl Ngo, MBBS, MMed,4
Deborah Jones, BSc, FAAO,5 and Graeme Young, PhD, FAAO6
SIGNIFICANCE: Results of this randomized, double-masked clinical trial demonstrate the effectiveness of the
MiSight soft contact lens in slowing myopia progression over multiple years.
PURPOSE: The purpose of this study was to quantify the effectiveness ofMiSight daily disposable soft contact lens
in slowing the progression of juvenile-onset myopia.
METHODS:Myopic children (spherical equivalent refraction, −0.75 to −4.00 D; astigmatism, <1.00 D) aged 8 to
12 years with no prior contact lens experience were enrolled in a 3-year, double-masked, randomized clinical trial
at four investigational sites in four countries. Subjects in each group were matched for age, sex, and ethnicity and
were randomized to either aMiSight 1-day contact lens (test) or Proclear 1-day (control; omafilconA) and worn on a
daily disposable basis. Primary outcome measures were the change in cycloplegic spherical equivalent refraction
and axial length.
RESULTS: Of the subjects enrolled, 75.5% (109/144) completed the clinical trial (53 test, 56 control). Unad-
justed change in spherical equivalent refraction was −0.73D (59%) less in the test group than in the control group
(−0.51 ± 0.64 vs. –1.24 ± 0.61 D, P < .001). Mean change in axial length was 0.32 mm (52%) less in the test
group than in the control group (0.30 ± 0.27 vs. 0.62 ± 0.30 mm, P < .001). Changes in spherical equivalent re-
fraction and axial length were highly correlated (r = −0.90, P < .001). Over the course of the study, there were no
cases of serious ocular adverse events reported. Four asymptomatic corneal infiltrative (one test, three control)
events were observed at scheduled study visits.
CONCLUSIONS: Results of this clinical trial demonstrate the effectiveness of the MiSight daily disposable soft
contact lens in slowing change in spherical equivalent refraction and axial length.
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Myopia represents a growing public health issue, affecting 33%
of adults in the United States1 and markedly higher proportions in
Asia.2–4 Increasing myopia is associated with increased risk of ret-
inal detachment,5 glaucoma,6 cataract,7 andmyopic retinopathy.8
Higher levels of myopia are also associated with increased disabil-
ity9,10 and poorer refractive surgery outcomes.11
In the past decade, there has been increased research activ-
ity aimed at slowing the progression of myopia by optical
methods, including overnight corneal reshaping contact lenses
(orthokeratology)12–14 and soft contact lenses incorporating
multifocal or aspheric optics,15–24 and these have shown promise
to slow myopia progression.
Studies of the mechanisms that regulate refractive develop-
ment in nonhuman primates show that hyperopic defocus can in-
duce excessive eye growth and myopia and that myopic defocus
can retard or reverse eye growth.25 Further research has shown that
eye growth can be manipulated when defocus, particularly myopic
defocus, is presented simultaneously with an additional optical
power. These simultaneous optics are typically used with concen-
tric alternating powers in a zonal design within the lens optic and
are commonly referred to as “dual-focus optics.” Lenses with
dual-focus optics have been used in a number of animal models,
such as chickens, guinea pigs, marmosets, and rhesus monkeys,
with the aim of retarding eye growth. All of these studies26–32 have
consistently shown that adding simultaneousmyopic defocus to ei-
ther hyperopic or plano correction resulted in reduced eye growth
when compared with the control animals or fellow control eyes.
This principle of applying myopic defocus via a dual-focus opti-
cal design has been studied in clinical trials of human subjects.
Anstice and Phillips15 evaluated a dual-focus soft contact lens in
children aged 11 to 14 years. This dual-focus design had a central
zone containing the distance correction with concentric peripheral
zones, alternating myopic defocus (additional positive power) with
distance correction power. The intent of this optical design was to
fully correct refractive error but simultaneously create myopic
defocus in all directions of gaze. The central correction zone was
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made sufficiently large for good visual acuity, but also to ensure
that normal accommodation would be stimulated for near work.
The zone diameters were designed to achieve constant presenta-
tion of myopic defocus to the retina. The dual-focus lens was com-
pared in a contralateral study design with a single-vision soft
contact lens. The mean 10-month change in spherical equivalent
refraction in the eye wearing the dual-focus lens was significantly
less than that in the contralateral eye wearing the single-vision lens
(−0.44 vs. −0.69 D). The mean axial elongation was also signifi-
cantly less with the dual-focus lenses (0.11 vs. 0.22mm) thanwith
the single-vision lenses.
This dual-focus optical design is the basis for the MiSight soft
contact lens (CooperVision, Inc., Pleasanton, CA). Myopia progres-
sion was recently studied in 89 children aged 8 to 12 years in a
2-year parallel-group study comparing MiSight with standard
single-vision spectacles.23 In this study, the mean change in
spherical equivalent refraction and the mean axial elongation
were significantly less in the MiSight group than in the spectacle
control group (−0.45 vs. −0.74 D, 0.28 vs. 0.44 mm).
The purpose of the current study is to report the results from a
clinical trial of MiSight lenses with dual-focus optics compared
with a single-vision contact lens of the same lensmaterial and over-
all geometry. The clinical trial was designed to quantify the effec-
tiveness of the MiSight lenses for slowing juvenile-onset myopia
progression. The primary outcomes for effectiveness were change
of cycloplegic spherical equivalent refractive error and axial length
over the 3-year period. Additional end points included assessment
of best-corrected visual acuity and subjective responses.
METHODS
Study Design
This study was a multicenter, parallel-group, double-masked, ran-
domized clinical trial (ClinicalTrials.gov identifier: NCT01729208) of
a daily wear, daily disposablemyopia control soft contact lens com-
pared with a standard daily disposable lens. The duration of the
study was 3 years.
The study was performed at four investigational sites: University
of Minho, Portugal; Aston University, United Kingdom; National
University Hospital, Singapore; and the University of Waterloo,
Canada. The study was conducted in conformance with the ethical
principles in the Declaration of Helsinki, with the International
Conference on Harmonization Good Clinical Practice guidelines
and all applicable local regulations. The protocol, consent, and as-
sent documents, along with all recruitment materials, were ap-
proved by each institution's institutional review board before
commencing the study.
The test product, MiSight, and the control lenses, Proclear
1-day (CooperVision, Inc.), are both soft (hydrophilic) contact
lenses composed of omafilcon Amaterial. The study contact lenses
were identical for both material and lens overall geometry and dif-
fered only in the optical design of the contact lens.
To ensure standardized measurements across sites, all sites
were provided with the same protocol and trained before study ini-
tiation. Identical equipment calibration instructions were imple-
mented for each site.
Subjects were recruited between November 2012 and April
2014. An assent document was explained to, read, and signed by
each potential study subject before enrollment in the study. Simi-
larly, a consent document was explained to, read, understood,
and signed by a parent or legal guardian of the subject
before enrollment.
All the inclusion and exclusion criteria are listed in Table 1.
Children with spherical equivalent refractive error between −0.75
and −4.00 D inclusive with less than 1.00 D of astigmatism or an-
isometropia were eligible for the study. The study population was
children aged 8 to <13 years at the baseline examination with
targeted enrollment of a minimum of 50% of the study population
in the 8- to 10-year age group.
At baseline, subjects were assessed for eligibility, which in-
cluded ocular characteristics such as refraction, visual acuity, bin-
ocular status, and ocular health (Table 1). Subjective refraction
was performed using a phoropter and projector chart at 6 m.
Cycloplegic autorefraction and axial length measurements were
performed as described in detail hereinafter.
Eligible subjects were sequentially randomized into either the
MiSight or control group (1:1 ratio). The randomization procedure
was stratified by clinical site and age group using a random per-
muted block design to achieve the 50% target of the younger-age
group. The randomization log was created centrally by the contract
research organization using a random number–generating com-
puter program. Each clinical site was given a randomization log
to assign the order in which subjects were dispensed the lens
types. The randomization log was stored in the study documenta-
tion, so all investigators could access it, but the study product
was coded (lens A and lens B) and the randomization log only
had the lens codes listed on it. This code was also the only identi-
fying feature on the study product. Participants and their parents
were masked.
A lens-fitting procedure was performed where the contact lens
power for the subject was finalized, and acceptable lens fitting
was confirmed. The subject was dispensed once he/she had suc-
cessfully completed training for insertion and removal of the con-
tact lenses. Both the MiSight and control lenses were used
following a daily wear, daily disposable modality. Progress was
monitored at follow-up visits at 1 week, 1 month, and 6, 18, 24,
30, and 36 months.
Cycloplegic spherical equivalent refraction and axial length
were assessed at baseline and at the annual follow-up visits.
Cycloplegia was produced by first instilling one drop of anesthetic,
either 0.5% proparacaine or 0.4% benoxinate, in each eye. One
minute later, one drop of 1% tropicamide was instilled in each
eye, followed by a second drop 5 minutes later. The examiner
waited at least 25minutes before conducting further assessments.
Cycloplegic refraction was measured using the Grand Seiko
Binocular Auto-refractor/Keratometer WR-5100K or WAM-5500
(Grand Seiko Co., Hiroshima, Japan). Subjects were instructed to
view a 4-m distance target one line larger than their best acuity;
subsequently, 10measurements were taken per eye and later aver-
aged. Axial length was measured using the IOLMaster (Carl Zeiss
Meditec, Dublin, California), with the subject fully cyclopleged.
Subjects were instructed to view the internal fixation target, and
10 measurements were taken of each eye.
Visual acuity was assessed using ETDRS Revised 2000 Series
Charts (Precision Vision, Woodstock, IL) using by-letter scoring
(0.02 logMAR). The charts were standardized to a luminance of
85 cd/m2. With the subject wearing the appropriate distance vision
correction and left eye covered, the subject began at 20/50 line,
reading the first letter on each successive line until he/she made
an error. When the subject made an error, he/she was asked to read
progressively larger lines until the subject was able to correctly
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www.optvissci.com Optom Vis Sci 2019; Vol 00(00) 2
identify all five letters on a line. The subject continued reading until
three or more letters were missed on a given line. Visual acuity was
recorded in logMAR to the nearest letter, including the final read
line. Near visual acuity was measured in logMAR notation with
Near Point Flip Charts (Precision Vision) held at 40 cm. The same
protocol for measuring distance vision was used to assess near vi-
sion under the same lighting conditions. Refractive status was
assessed at each visit before cycloplegia. A change in lens power
was provided at any study visit when subjective overrefraction was
equal or greater than 0.50 D or a clinically meaningful improve-
ment in visual acuity could be achieved (greater than½ line). Lens
fit and ocular health were also assessed at these visits.
Subjective feedback was obtained from both the participants
and the parents via questionnaires at each follow-up visit. Ques-
tionnaires targeted information for lens handling along with assess-
ments of comfort, vision, and overall satisfaction. Each question
offered five Likert-type responses. The subjects were given ample
time and asked to complete the questionnaire by themselves. A
member of the site staff was available to answer any queries and
to help the subject understand the question but was instructed
not to help the subject with the answer.
For the purposes of demonstrating the general acceptance of
the contact lenses in this trial population, this publication will pres-
ent findings only for lens handling and overall satisfaction from the
extensive questionnaire. Subjects were invited to rate their contact
lens handling experience to choose from the following: really easy,
kind of easy, neither easy nor hard, kind of hard, or really hard. For
the overall satisfaction rating for wearing both their spectacles and
contact lenses, the following choices were given to the subjects:
I like them the best, I kind of like them, neither like them nor do
not like them, I do not like them, and I cannot stand them.
Wearing time was collected by asking participants their typi-
cal lens insertion and removal times on a typical weekday and
weekend and how many days in a week the lenses were typically
worn. The wear time was calculated from these responses for
each participant.
The primary outcomes for safety were assessed using slit-lamp
biomicroscopy findings and ocular adverse event rates between
TABLE 1. Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Be between 8 and 12 y of age inclusive at baseline examination Current or prior contact lens wear
The participant has been given a clear explanation, then read,
understood, and signed the informed assent form.
Subject is currently or within 30 d before this study has
been an active participant in another clinical study
The participant has been given a clear explanation, then read,
understood, and signed the informed assent form.
Parent/guardian or close relative is a member of the office staff,
including the investigator(s)
The parent or legal guardian has been given a clear explanation,
then read, understood, and signed the informed consent form.
Current or prior use of bifocals, progressive addition
lenses, atropine, pirenzepine, or any other myopia control treatment
Willingness to adhere to protocol, agreement to maintain
the visit schedule
Birth earlier than 30 wk or <1500 g (3.3 lb) at birth
Along with their parent or guardian, agree to maintain the visit schedule
and be able to keep all appointments as specified in the study protocol
for the duration of the study
Regular use of ocular medications, artificial tears, or wetting agents
Acceptance of either the control or test lens as assigned
by randomization
Current use of systemic medications, which may affect contact lens wear,
tear film production, pupil size, accommodation, or refractive state
Agreement to wear the assigned contact lenses for a minimum of
10 hours per day, at least 6 days per week, for the duration of the 3-y study.
Agreement to inform the study investigator if this schedule is interrupted
A known allergy to fluorescein, benoxinate, proparacaine, or tropicamide
Possess wearable and visually functional eyeglasses A history of corneal hypoesthesia (reduced corneal sensitivity), corneal
ulcer, corneal infiltrates, ocular viral or fungal infections, or other
recurrent ocular infections
Be in good general health, based on his/her and
parent's/guardian's knowledge
Strabismus by cover test at distance or near wearing distance correction
Best-corrected visual acuity by manifest refraction of +0.10 logMAR
(20/25) or better in each eye
History of ocular or systemic diseases, including
those that could influence refractive development
Meet the following refractive criteria determined by cycloplegic
autorefraction at baseline:
(a) Spherical equivalent refractive error: between −0.75
and −4.00 D inclusive
(b) Astigmatism: ≤−0.75 D
(c) Anisometropia: <1.00 D
Keratoconus or an irregular cornea
Contraindications for contact lens wear including giant papillary
conjunctivitis of grade 2 or worse and allergic or seasonal conjunctivitis
Subject seems to exhibit poor personal hygiene (that in
the investigator's opinion might prevent safe contact lens wear)
or the investigator for any reason considers that it is not in
the best interest of the subject to participate in the study
MiSight Myopia Control— Chamberlain et al.
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the MiSight and control groups. Adverse events were classified and
reported according to a pre-determined list detailed in the study
protocol. Slit-lamp signs were graded using a 0- to 4-point scale de-
veloped from the guidance illustrated in the regulatory standard
ISO11980, with 0 representing none or absent findings and 4
representing severe. Unique supplementary descriptions were
added to this scale for specific tissue grading.
Sample Size Estimation
The target effect size for sample size calculation was specified
as “0.25 D per year (i.e., 0.75 D for 3 years).” This therefore pro-
duced two aims for the primary effectiveness end point; the first
was to detect 0.25 D between groups for each year of the study.
Using 0.25 D per year as a target and assuming a standard devia-
tion of 0.50 D, it was estimated that 87 subjects per group would
be needed (two-sample t test with equal variance, α = 0.05,
power = 90%). The protocol anticipated an enrollment target of
150 eligible subjects per group to account for attrition (14%, or
42 subjects per year) over the 3-year period.
However, because of a longer-than-expected recruitment pe-
riod, it was evident that the number of subjects enrolled would be
smaller than this target. As a consequence, the sample size re-
quirements for the second aim, which was to detect a 0.75-D dif-
ference between the groups for 3 years, were applied. Assuming a
standard deviation of 0.50 D, 22 subjects (11 per group) would
have been needed (two-sample t test, α = .05, power = 90%) to
complete the study. As such, the final sample size of 144 eligible
subjects was more than adequate to detect the primary effective-
ness end point.
Statistical Methods
Baseline data for theMiSight and control groups were evaluated
by the two-sample t test (continuous data), Mann-Whitney U test
(categorical data), or Fisher exact test (nominal data). Imbalances
of potentially confounding variables that were identified between
the two groups were addressed by including them as covariates in
the final analysis. All inferences were carried out with the type I er-
ror rate controlled at 5%.
Data were pooled from all sites based on three factors: (1) com-
mon protocol, (2) common data collection procedures, and (3)
closely monitored protocol compliance. As specified in the protocol,
an analysis of the interaction of lens type by site was performed and
found not significant (P > .10) for the primary outcome variables.
The primary outcome measures for effectiveness were checked
for normality and first compared between treatment groups using a
t test. These primary outcomes were also compared using linear
mixed models. Comparisons between the MiSight and control
lenses were carried out using two-sided confidence interval con-
structed least-square mean differences at each follow-up visit.
The model included treatment (lens type), visit, site, and the inter-
actions: visit by treatment and site by treatment as fixed effects;
age, sex, weekday wearing time, weekend wearing time, and base-
line value as fixed covariates; and subject (nested in site) and eye
as random effects. The inclusion of eye as a random effect ac-
counts for any correlation between eyes. The analyses included
all evaluable subjects who did not have a protocol deviation that
rendered data unsuitable for inclusion. If a subject missed a pri-
mary outcome visit, no data were included for that visit, but all
other visits with evaluable data for that subject were included. Data
from discontinued subjects were included up to the point of their
discontinuation. A statistical difference was concluded if the
95% confidence limit of the mean difference was greater than zero
(test minus control). The questionnaire responses were compared
with linear mixed models. The model included treatment (lens
type), visit, site, and the interactions.
The statistical analyses were performed using SAS version 9.4
(SAS Institute, Cary, NC).
RESULTS
Baseline Data
Table 2 summarizes the demographics for all enrolled subjects.
There were no statistically significant differences between the
MiSight and control groups with respect to the critical demographic
factors that have been associated withmyopia progression. At base-
line, the mean cycloplegic spherical equivalent refractive errors were
−2.02 ± 0.77 D for the MiSight lens group and −2.19 ± 0.81 D for
the control lens group. Axial length was also similar between the
groups: 24.42 ± 0.70 and 24.46 ± 0.66 mm for the MiSight and
control lens groups, respectively.
Subject Accountability
Fig. 1 shows the flow of participants through the clinical trial
from recruitment to study completion and analysis. Of the 187 sub-
jects who were screened, 144 were eligible and randomized. This
number comprised 21 subjects in Portugal, 28 in the United
Kingdom, 31 in Singapore, and 64 in Canada. The main reasons
for ineligibility were spherical refractive error (15), cylinder (7),
and anisometropia (5). Of those allocated treatment, six had unac-
ceptable lens fits (three MiSight and three control), and two had
challenges with lens insertion and removal, whereas one control
subject elected to withdraw from the study during the first week.
TABLE 2. Subject demographics at baseline
Variable Control (n = 74) MiSight (n = 70) P
Age (y) 10.1 ± 1.4 10.1 ± 1.3 .83
Range 8–12 8–12
<10 42 (57%) 40 (57%)
10–12 32 (43%) 30 (43%)
Male 37 (50%) 38 (54%) .62
Female 37 (50%) 32 (46%)
White (European) 40 (54%) 39 (56%) .79
East Asian 18 (24%) 16 (23%)
West Asian 7 (9%) 5 (7%)
Other 4 (5%) 2 (3%)
Mixed 5 (7%) 8 (11%)
(n = 148 eyes) (n = 140 eyes)
Cycloplegic spherical
equivalent (D)
−2.19 ± 0.81 −2.02 ± 0.77 .08
Range −0.83 to −4.00 −0.77 to −3.77
Cylinder (D) −0.40 ± 0.21 −0.40 ± 0.21 .82
Range 0.00 to −0.75 0.00 to −0.75
Axial length (mm) 24.46 ± 0.70 24.42 ± 0.66 .90
Range 23.0 to 27.0 22.7 to 26.0
MiSight Myopia Control— Chamberlain et al.
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Thus, 135 subjects were dispensed the allocated intervention,
ranging between 21 and 60 subjects per site.
One hundred nine subjects completed the 3-year clinical trial
(53 MiSight and 56 control). One subject in the MiSight group
was excluded from the 36-month analysis because the subject
began a course of growth hormone treatment during the last
6 months of the study. The total retention rate for the study
was 75.5%.
Compliance to the protocol-specified wearing time was high.
The mean wearing times reported for weekdays at the 36-month
visit were 13.3 ± 1.5 hours per day for the control group and
13.7 ± 1.5 for the MiSight group, and this difference was not sig-
nificant. The mean wearing times reported for weekends were
slightly lower but were 12.4 ± 0.9 and 12.1 ± 1.2 hours per day
for the control and MiSight groups, respectively. The linear mixed
model showed no differences between lens types for wear time at
weekdays or weekends (P > .05). Subjects also reported the num-
ber of days per week that lenses were worn. The mean reported
wearing times were at least 6.5 days per week for both lens groups.
None of the above measures were significantly different between
the groups.
Refractive Error Progression
The MiSight group exhibited less progression in cycloplegic
spherical equivalent refraction than did the control group at
each of the annual follow-up visits (Fig. 2, Table 3). In compar-
ison with the control group, the changes in cycloplegic spherical
equivalent refraction were on average 0.40 D less (−0.58 vs.
−0.18 D) with MiSight at 12 months, 0.54 D less at 24 months,
FIGURE 1. Flowchart to indicate the disposition of subjects from screening to study completion.
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and0.73D less at 36months. These differenceswere statistically sig-
nificant at each time point (Student t test, P < .0001), representing
myopia control effects of 69%, 59%, and 59%, respectively.
After adjusting for factors detailed in Statistical Methods, the
least-square estimated mean progression was calculated. The esti-
matedmean progression and differences are shown in Table 4. The
adjusted differences in progression rate remained statistically sig-
nificant at all follow-up visits.
Fig. 3 shows the distribution of individual subject's change in
spherical equivalent refraction after 36 months. Among the
MiSight lens–wearing eyes, 41% showed no clinically meaningful
change in spherical equivalent refraction (defined as −0.25 D or
less change) in comparison to 4% of the eyes in the control lens
group. Conversely, 62% of the control lens–wearing eyes had
progressed by more than −1.00 D compared with 18% of the
MiSight eyes.
Axial Elongation
The MiSight group exhibited less axial length growth than did
the control group at each of the annual follow-up visits. At
12 months, the change in axial length was 0.24 mm in the control
group versus 0.09 mm in the MiSight group, representing on aver-
age a 0.15-mm less growth in the MiSight lens group. At 24 and
36 months, the change in axial length growth was 0.24 and
0.32 mm less in the MiSight lens group, respectively (Fig. 4,
Table 3). These differences were statistically significant at each
time point, representing myopia control effects of 63%, 53%,
and 52%, respectively.
After adjusting for factors detailed in Statistical Methods, the
least-square estimated mean change in axial length was calcu-
lated. The estimatedmean change and differences between groups
are shown in Table 4. The differences in axial length were statisti-
cally significant at all follow-up visits.
FIGURE 2. Mean unadjusted changes in spherical equivalent refrac-
tive error (D) for the test (MiSight) and control (Proclear 1-day) study
groups. The filled and open symbols represent the MiSight and control
groups, respectively, for the 36-month study period. The error bars de-
note the 95% CI of the mean changes. The mean unadjusted differ-
ences were 0.40 D less with MiSight at 12 months, 0.54 D less at
24 months, and 0.73 D less at 36 months. CI = confidence interval.
TABLE 3.Myopia progression for spherical equivalent and axial length
Visit Study group n (Eyes)
Spherical equivalent
(D ± SD) Change (D) 95% CI
Baseline Control 148 −2.19 ± 0.81
MiSight 140 −2.02 ± 0.77
12 mo Control 120 −2.80 ± 1.01 −0.58 ± 0.41 −0.51 to −0.66
MiSight 116 −2.17 ± 0.85 −0.18 ± 0.39
24 mo Control 120 −3.13 ± 1.08 −0.92 ± 0.53 −0.82 to −1.01
MiSight 110 −2.33 ± 0.92 −0.38 ± 0.52
36 mo Control 112 −3.45 ± 1.14 −1.24 ± 0.61 −1.12 to −1.35
MiSight 104 −2.52 ± 0.98 −0.51 ± 0.64
Axial length (mm) Change (mm) 95% CI
Baseline Control 148 24.42 ± 0.66
MiSight 140 24.46 ± 0.70
12 mo Control 120 24.68 ± 0.66 0.24 ± 0.15 0.21 to 0.27
MiSight 116 24.52 ± 0.69 0.09 ± 0.13
24 mo Control 120 24.88 ± 0.70 0.45 ± 0.23 0.41 to 0.50
MiSight 110 24.60 ± 0.64 0.21 ± 0.22
36 mo Control 112 25.07 ± 0.74 0.62 ± 0.30 0.57 to 0.68
MiSight 104 24.76 ± 0.66 0.30 ± 0.27
CI = confidence interval.
MiSight Myopia Control— Chamberlain et al.
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Factors Impacting Progression
Statistically significant factors affecting refractive error progres-
sion and axial length elongation included lens type, investigative
site, study visit, age, and sex (Table 5). Ethnicity and baseline my-
opia (refractive error or axial length) were not significant. There was
a significant interaction of lens type and visit for refractive error
progression and axial elongation, suggesting that the rate of change
of the two lens types is different over the years. There was no signif-
icant interaction between lens type and site, suggesting that the
myopia progression for both lens types was independent of
investigative sites. The interaction of lens type with age, sex, or
baseline myopia was not significant and was removed from the
model. The absence of significant interactions of lens type with
age, sex, baseline myopia, or investigative site demonstrates that
the myopia control effect is independent of these factors in this
study population.
Correlation between Changes in Axial Length and
Refractive Error
There is a strong relationship between increasing myopia with
increasing axial length. With the MiSight and control combined
TABLE 4. Least-square mean estimates for spherical equivalent and axial length progression
Visit Study group Spherical equivalent change (D ± SD) Difference (D ± SD) 95% Confidence interval P
12 mo Control −0.64 ± 0.07 0.38 ± 0.09 0.21 to 0.55 <.0001
MiSight −0.27 ± 0.07
24 mo Control −0.99 ± 0.07 0.52 ± 0.09 0.35 to 0.69 <.0001
MiSight −0.47 ± 0.07
36 mo Control −1.31 ± 0.08 0.67 ± 0.09 0.49 to 0.84 <.0001
MiSight −0.65 ± 0.07
Axial length change (mm) Difference (mm) 95% Confidence interval P
12 mo Control 0.23 ± 0.03 −0.13 ± 0.04 −0.21 to −0.05 <.002
MiSight 0.10 ± 0.03
24 mo Control 0.45 ± 0.03 −0.22 ± 0.04 −0.30 to −0.14 <.0001
MiSight 0.23 ± 0.03
36 mo Control 0.62 ± 0.03 −0.28 ± 0.04 −0.36 to 0.20 <.0001
MiSight 0.34 ± 0.03
FIGURE 3. Frequency distribution of change in refractive error from baseline to 36 months. The filled and open bars represent the MiSight and control
groups, respectively.
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data, there were statistically significant correlations at each of the
follow-up visits (P < .0001). These correlations became stronger
as the study progressed. At 12 months, the correlation coeffi-
cient (R) was −0.77; at 24 months, the R value was −0.86; and
at 36 months, the R value was −0.90.
The correlations were also statistically significant at each
follow-up visit when considered separately for theMiSight and con-
trol groups. At 36 months, the correlation coefficients were −0.89
(P < .0001) for the MiSight group and −0.85 (P < .0001) for the
control group.
The slope for all subjects at 36 months was −0.42 (95% confi-
dence interval, −0.45 to −0.39), showing that a 0.1-mm change in
axial length corresponded to 0.24-D change inmyopia in this study
population. The slope did not vary significantly between treatment
groups or among sites.
Contact Lens Visual Acuity
At the dispensing visit, mean distance visual acuity with contact
lenses was within one letter for the MiSight lenses and control
lenses (−0.03 ± 0.06 vs. –0.05 ± 0.07 logMAR). Mean visual acu-
ity with contact lenses varied slightly at follow-up visits, possibly
due to refractive error changes that occurred since the last visit,
but did not differ by more than two letters at any visit. With spher-
ical overrefraction, best-corrected visual acuity with contact lenses
remained similar for the two lens types and within one letter at each
visit. Near visual acuity remained within one letter for the MiSight
and control lenses at each visit. The data for visual acuity are shown
in Table 6.
Subjective Responses
Responses to the question “How easy is it to put the lenses on
your eye?” were obtained. At the 1-month visit, a large proportion
of children (>80%) in each group described insertion of lenses as
“kind of easy” or “really easy” (top 2 box responses). Over the re-
mainder of the study period, more than 90% of subjects rated
within the top 2 box category. There was no difference between
study groups in the response to this question (P = .64). With re-
spect to lens removal, the responses to “How easy is it to take the
lenses out of your eye?” remained in the top 2 boxes for more than
90% of the subjects throughout all visits of the study; again, there
was no difference between study groups for this response (P = .99).
A positive response to the general experience of wearing contact
lenses was also observed. For the question “How much do you like
wearing your contact lenses?” an average of 97% of children chose
one of the top 2 responses across all visits of the study. There was
no difference between study groups in the response (P = 1.00).
This was compared with a less positive response for spectacles,
with an average of 57% choosing one of the top 2 responses to
the question “How much do you like wearing your spectacles?”
across all visits. The difference between groups approached
statistical significance (P = .05), In general, this was due to
higher variation in the response across the groups, throughout the
study period.
FIGURE 4. Mean unadjusted changes in axial length (in millimeters)
for the test (MiSight) and control (Proclear 1-day) study groups. The
filled and open symbols represent the MiSight and control groups, re-
spectively, for the 36-month study period. The error bars denote the
95% CI of the mean changes. The mean unadjusted differences were
0.15mm less withMiSight at 12months, 0.24mm less at 24months,
and 0.32 mm less at 36 months. CI = confidence interval.
TABLE 5. Tests of fixed effects for primary variables
Model term
Refractive error Axial length
df F P df F P
Lens type 1, 106 44.31 <.0001 1, 106 33.29 <.0001
Site 3, 104 13.26 <.0001 3, 106 4.90 .003
Visit 2, 209 119.89 <.0001 2, 209 245.13 <.0001
Age 1, 103 7.78 .006 1, 108 13.75 .0003
Sex 1, 103 9.20 .006 1, 122 4.43 .04
Ethnicity 4, 104 0.59 .67 4, 106 0.11 .98
Baseline spherical equivalent/axial length 1, 361 2.22 .14 1, 364 0.26 .61
Lens type  site 3, 105 1.08 .36 3, 107 1.70 .17
Lens type  visit 2, 209 9.03 .0002 2, 209 14.89 <.0001
Site  visit 6, 209 2.21 .05 6, 209 5.31 <.0001
Lens type  site  visit 6, 209 1.14 .34 6, 209 0.81 .56
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Safety Evaluation
There were no serious (events that are vision-threatening and result
in permanent impairment of a body function or permanent damage to
a body structure) or significant (events that usually are symptomatic
but are non–vision-threatening and result in temporary impairment of
a body function or temporary damage to a body structure) ocular ad-
verse events reported in the 3-year study. There were 18 events (11
subjects) in subjects wearing the MiSight lens and 12 (10 subjects)
with the control lens. Seven events (six subjects) with the test lens
and seven events (five subjects) with the control lens were considered
lens related. Four of these were asymptomatic corneal infiltrative
events, one in the MiSight lens and three in the control lens group.
The remainder of these events included foreign body, bilateral allergic
reaction, unilateralmild pannus (requiring temporary discontinuation),
superficial punctate corneal staining, a unilateral subconjunctival
hemorrhage, and a case of irritation with the lens located under the
eyelid. There were no reports of loss of best-corrected visual acuity.
There was only one instance of a slit-lamp finding of grade 3 or
more. Grade 3 palpebral roughness was recorded in a MiSight
lens–wearing eye at the 1-month visit. This was attributed to a
TABLE 6. BCVA with contact lenses
n (eyes)
Presenting
contact lens VA
BCVA with
spherical
overrefraction
Presenting
contact lens
near VA
Control
Dispensing 148 −0.05 ± 0.07 −0.05 ± 0.07 −0.07 ± 0.11
12 mo 120 +0.01 ± 0.13 −0.07 ± 0.08 −0.11 ± 0.11
24 mo 120 +0.00 ± 0.13 −0.07 ± 0.08 −0.11 ± 0.09
36 mo 112 +0.00 ± 0.10 −0.05 ± 0.07 −0.10 ± 0.08
MiSight
Dispensing 140 −0.03 ± 0.06 −0.03 ± 0.06 −0.05 ± 0.10
12 mo 116 −0.04 ± 0.09 −0.07 ± 0.06 −0.09 ± 0.10
24 mo 110 −0.04 ± 0.10 −0.07 ± 0.08 −0.11 ± 0.09
36 mo 104 −0.01 ± 0.11 −0.05 ± 0.07 −0.09 ± 0.09
All values are in logMAR (mean ± SD). BCVA = best-corrected visual
acuity; VA = visual acuity.
TABLE 7. Summary of previous studies of soft contact lenses on myopia progression
Authors
Duration
(mo)
Analyzed
test/
control
Discontinued
(%)
Study
design
Treatment
lens
Control
lens Age (y)
Entry Rx
range (D)
Treatment effect
for axial length
Axial length
difference (mm)
Myopia
control (%)
Anstice
and Phillips15
10 35/35* 13 Randomized
paired eye,
crossover
Dual focus Soft lenses 11–14 −1.25 to −4.50 0.11 49
Sankaridurg
et al.16
12 43/39 18 Prospective Progressive
periphery
Spectacles 7–14 −0.75 to −3.50 0.15 38
Fujikado
et al.18
12 11/13 0 Randomized
masked,
crossover
Menicon
low-addition
(Nagoya, Japan)
Soft lenses 10–16 −0.75 to −3.50 0.05 25
Aller et al.21 12 39/40 9 Randomized,
masked
Acuvue Bifocal
(Vistakon, a division
of Johnson &
Johnson Vision
Care, Jacksonville,
FL)
Soft lenses 8–18 −0.50 to −6.00 0.19 79
Cheng et al.22 12 53/59 16 Randomized,
masked
Positive spherical
aberration
Soft lenses 8–11 −0.75 to −4.00 0.14 39
Walline et al.17 24 27/27 33 Historical
control
Proclear
multifocal
Soft lenses 8–11 −1.00 to −6.00 0.12 29
Allen et al.24 24 45/50 33 Randomized
masked
Aberration
controlled
monofocal
Soft lenses 14–22 −0.75 to −10.00 −0.01 −0.1
Lam et al.19 24 65/63 42 Randomized,
masked
Custom
concentric
bifocal
Soft lenses 8–13 −1.00 to −5.00 0.12 32
Paune et al.20 24 19/21 44 Prospective Radial refractive
gradient
Spectacles 9–16 −0.75 to −7.00 0.14 27
Ruiz-Pomeda
et al.23
24 41/33 7 Randomized,
masked
MiSight Spectacles 8–12 −0.75 to −4.00 0.17 36
Present study 36 52/56 19 Randomized,
masked
MiSight Soft lenses 8–12 −0.75 to −4.00 0.32 52
Rx = refraction.
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foreign body andwas not noted at subsequent follow-up visits. Palpe-
bral roughness was graded from 0 to 4 as follows: 0 (none), uniform
satin appearance of the conjunctiva; 1 (trace), slight conjunctival in-
jection without texture; 2 (mild), mild or scattered papillae/follicles
less than 1 mm in diameter; 3 (moderate), (a) significant papillae/
follicles less than 1 mm in diameter and/or marked conjunctival in-
jection and (b) staining of the top of one papilla; and 4 (severe), (a)
localized or generalized papillae/follicles 1 mm or more in diameter
and (b) staining of the top of more than one papilla.
DISCUSSION
The findings of this 3-year randomized clinical trial demonstrate
that myopia progression is significantly slowed by the MiSight
soft contact lens. MiSight lenses showed less unadjusted refrac-
tive error change by 0.40 D at 12 months, 0.54 D at 24 months,
and 0.73 D at 36 months compared with the single-vision control
contact lens. This was closely mirrored by a reduction in axial elon-
gation of 0.32 mm at 36 months in the MiSight group. The strong
correlation between axial elongation and refractive error progres-
sion demonstrates that the lenses slow myopia progression by re-
ducing the rate of axial growth.
Table 7 presents a summary of other clinical trials that utilized
soft contact lenses for myopia control, arranged by trial duration.
This current clinical trial presents 3-year results, whereas all of those
summarized in Table 7 are 1- or 2-year studies. The reduction inmy-
opia progression reported here approaches the greatest observed ef-
fect size from previously published studies. However, the absence of
studies of similar duration makes comparison of effect size difficult.
Ruiz-Pomeda et al.23 recently published results of a 2-year clin-
ical trial assessing myopia progression with the MiSight lens
comparedwith a control group wearing single-vision spectacles. Al-
though the study used a different control group and different statis-
tical methods for accounting for imbalances between groups at
baseline compared with the current study, overall the results of
the studies are similar. In the study by Ruiz-Pomeda et al., the
mean change in axial length at the 12-month visit was 0.12 mm
for theMiSight lens and 0.24mm for the control group, for a differ-
ence in elongation of −0.12 mm. At the 24-month visit, the differ-
ence in axial elongation was −0.16 mm (0.28 vs. 0.44 mm).
These findings are within the 95% confidence intervals
(Table 4) for adjusted axial length differences of this current study
(95% confidence intervals, −0.21 to −0.05 [year 1] and −0.30 to
−0.14 mm [year 2]).
The current clinical trial used a soft contact lens as the control
group. This is in line with the recommendation of the Food and
Drug Administration Public Workshop on Controlling the Progres-
sion of Myopia.33 The lenses were matched for all parameters, with
the exception of the dual-focus optical design of MiSight. This way,
if physiological effects are produced in either a myopic or hyper-
opic direction, whatever the underlying etiology, they should be
identical in the two groups, and thus, any refractive and axial
length differences between the two groups can be attributed to
the optical design.
The study was conducted in four countries and recruited an
ethnically diverse sample. Although myopia progression showed
variation among investigational sites, the reduction in myopic
progression with MiSight was statistically significant at all sites.
Some studies, although not all, have noted a difference in myopia
progression as a function of ethnicity.34–36 This study found no such
effect; furthermore, the interaction of lens type with ethnicity or lens
type with site when assessing spherical equivalent refraction and axial
length progressionwasnot significant, which implies generalizability of
themyopia control treatment across different regions and populations.
The high level of wearing time compliance (both hours and days
per week) for both groups did not provide sufficient variation to
evaluate the effect of wearing time on myopia progression reported
by some investigators.19
In line with other research, myopia progression varied with age,
with younger subjects progressing faster. However, the degree of
myopia control with MiSight was not impacted by this factor, sug-
gesting that MiSight works with similar treatment effect in younger
and older subjects. A similar finding is observed with sex, where fe-
male participants display higher myopia progression than do male
participants, also observed by Hyman et al.,36 but again, the inter-
action with treatment effect was not significant.
For both refractive error progression and axial elongation, there
was a persistence of myopia control effect across the 3 years of the
study. Themagnitude of the effect was highest in the first year of wear
but continued to accrue across the period of observation. In other
2-year studies of myopia control with multifocal soft contact lenses
(Table 7), the myopia control effect persisted and accrued over the
2 years.17,19,20 This is in contrast to the 3-year Correction of Myopia
Evaluation Trial (COMET) trial of progressive addition spectacles,37
where the adjusted treatment effect was 0.18 D with minimal to no
accrual in the subsequent 2 years.
A significant proportion of the MiSight group (41%) showed no
meaningful progression in spherical equivalent refraction (−0.25 D
or less change) over the duration of the trial. In contrast, only 4% of
control eyes showed a similar lack of progression (absolute risk reduc-
tion, 37%). The number of eyes needed to treat (=1/absolute risk re-
duction) to achieve this benefit is approximately three eyes (95%
confidence interval, 2.1 to 3.6). Therefore, for every three eyes
treated in this cohort, one eye will show nomeaningful myopic pro-
gression over a 3-year period.
Questionnaire responses collected throughout the study align
with previous studies38,39 that have shown that soft contact lenses
are well accepted by children. The children in this study showed
that they were able to achieve full-time wear, were able to handle
the lenses confidently, and had a positive response to contact lens
wear. Only one child discontinued for vision quality reasons over
the 3-year period. The overall retention rate compares very favor-
ably with previous studies (Table 7).
No serious ocular adverse events were observed during the 3-year
clinical trial, including no cases of microbial keratitis. Only four non-
significant corneal infiltrative events were reported over the 3-year
period, all asymptomatic and noted at scheduled visits. The absence
of serious or significant ocular adverse events supports the growing
acceptance that soft contact lenses are safe for use by children.40
Limitations
Enrollment was lower than the target because of recruitment
difficulties at some of the sites; however, subject retention was
high, and the sample size was sufficiently large to show differences
between the two lens types for the primary efficacy end point of
0.75 D at 3 years.
Subjects in this clinical trial were not withdrawn from treatment
to assess the extent to which the benefit is sustained. Some myopia
treatments with atropine have been shown to be susceptible to post-
treatment acceleration.41 Finally, the investigators had access to the
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randomization codes. Although these randomization codes were
only identified as “lens A” and “lens B,” theoretically an examiner
could have identified whether lens A was the experimental or
control assignment.
Summary
This 3-year randomized clinical trial, designed to evaluate the
safety and effectiveness of a soft contact lens intended to slow my-
opia progression in children, demonstrates the following:
• The progression of refractive error in children is significantly
reduced by the MiSight lens compared with a single-vision
soft contact lens.
• The axial elongation that underlies and is correlated with re-
fractive error progression is significantly less with the MiSight
lens compared with a single-vision soft contact lens.
• No safety concerns were evident for this population of chil-
dren who started daily disposable soft contact lens wear be-
tween 8 and 12 years of age.
• The high subject retention, long wearing time, and favorable
subjective ratings show that contact lens acceptance was
sustained across 3 years. This work supports previous find-
ings38,39 that soft contact lenses are well accepted by children.
Children as young as 8 years are able to achieve full-time
wear, handle the lenses confidently soon after initial fitting,
and achieve good comfort.
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